<DOC>
	<DOCNO>NCT00773422</DOCNO>
	<brief_summary>The purpose study examine medication think attenuate effect alcohol ( naltrexone ) smoke cessation medication ( varenicline ) affect ability resist smoking also subsequent ad-lib smoking , follow low-dose alcohol prim drink , non-treatment seek alcohol-drinking daily smoker .</brief_summary>
	<brief_title>The Effect Naltrexone Varenicline Alcohol-Mediated Smoking Lapse</brief_title>
	<detailed_description />
	<mesh_term>Naltrexone</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>age 2155 ability read write English alcoholdrinking smoker significant current medical condition would contraindicate smoking current DSMIV abuse dependence substance , nicotine dependence alcohol abuse . positive test result intake appointment urine drug screen conduct opiate , cocaine , benzodiazepine woman pregnant nursing suicidal , homicidal evidence current severe mental illness participant prescribe psychotropic drug 30 day prior study enrollment blood donation within past 6 week individual seek treatment smoking cessation drinking attempt quit smoking drinking within past 3 month specific exclusion administration naltrexone specify include chronic pain condition necessitate opioid treatment , evidence significant hepatocellular injury evidence SGOT SGPT &gt; 3x normal elevate bilirubin know allergy varenicline take H2blockers ( e.g. , Cimetidine ) participation within past 8 week study involve additive blood sample and/or interventional measure would consider excessive combination current protocol</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>smoke lapse behavior</keyword>
	<keyword>smoke cessation</keyword>
	<keyword>varenicline</keyword>
	<keyword>naltrexone</keyword>
	<keyword>medication effect smoke lapse behavior</keyword>
</DOC>